中华肿瘤杂志
中華腫瘤雜誌
중화종류잡지
CHINESE JOURNAL OF ONCOLOGY
2010年
4期
278-282
,共5页
陈清勇%江中勇%吴丽君%张宝燕%陆国华%周建英
陳清勇%江中勇%吳麗君%張寶燕%陸國華%週建英
진청용%강중용%오려군%장보연%륙국화%주건영
α-微管蛋白%多药耐药基因1%癌,非小细胞肺%免疫组织化学%印迹法,蛋白质%预后
α-微管蛋白%多藥耐藥基因1%癌,非小細胞肺%免疫組織化學%印跡法,蛋白質%預後
α-미관단백%다약내약기인1%암,비소세포폐%면역조직화학%인적법,단백질%예후
α-tubulin%MDR1 protein%Carcinoma,non-small-cell lung%Immunohistochemistry%Western blot%Prognosis
目的 探讨α-微管蛋白和多药耐药基因1(MDR1)在原发性非小细胞肺癌(NSCLC)中的表达特征及其临床意义.方法 采用免疫组化SP法检测158例NSCLC组织中α-微管蛋白和MDRI的表达情况,采用Western blot方法检测30例新鲜NSCLC组织及相应癌旁正常组织中α-微管蛋白和MDRI的表达,分析两者表达与肺癌生物学特性的关系.结果 α-微管蛋白和MDRI在NSCLC中的阳性表达率分别为65.2%和51.3%,而30例癌旁组织中均未见α-微管蛋白和MDRI阳性表达.Western blot检测结果显示,α-微管蛋白和MDR1在30例新鲜NSCLC组织中的表达(0.49±0.06和0.56±0.04)明显高于相应癌旁肺组织(0.07±0.01,0.65±0.02;t=3.693,t=6.769,P＜0.01).α-微管蛋白在Ⅰ～Ⅱ期与Ⅲ～Ⅳ期NSCLC中的阳性表达率差异有统计学意义(P＜0.01),在中、高分化NSCLC中的阳性表达率明显低于低分化NSCLC(P＜0.01).α-微管蛋白的表达与患者的年龄、性别、组织类型、肿瘤大小以及淋巴结转移无明显关系(P＞0.05),MDR1的表达与患者的年龄、性别、临床分期、肿瘤大小、病理分级以及淋巴结转移无关(P＞0.05).在不同组织类型中,MDR1的表达水平有较大差异,肺腺癌中的MDR1阳性表达率明显高于鳞癌和大细胞癌(P＜0.01).α-微管蛋白和MDR1的表达与化疗疗效无关(X2=0.69,X2=1.30,P＞0.05).单因素生存分析显示,α-微管蛋白和MDR1阴性患者的5年生存率分别为30.7%和28.5%,明显高于α-微管蛋白和MDR1阳性表达患者(13.5%和11.8%),差异有统计学意义(X2=20.69,X2=15.52,P＜0.01).多因素生存分析显示,α-微管蛋白(RR=3.287,P=0.006)和临床分期(RR=1.954,P=0.025)可作为独立的预后指标.α-微管蛋白和MDR1在肺癌组织中的表达无明显相关性(r=0.093,P＞0.05).结论 α-微管蛋白和MDR1在肺癌的发生和恶性进展中有一定作用,联合检测可作为判断肺癌预后的重要指标.
目的 探討α-微管蛋白和多藥耐藥基因1(MDR1)在原髮性非小細胞肺癌(NSCLC)中的錶達特徵及其臨床意義.方法 採用免疫組化SP法檢測158例NSCLC組織中α-微管蛋白和MDRI的錶達情況,採用Western blot方法檢測30例新鮮NSCLC組織及相應癌徬正常組織中α-微管蛋白和MDRI的錶達,分析兩者錶達與肺癌生物學特性的關繫.結果 α-微管蛋白和MDRI在NSCLC中的暘性錶達率分彆為65.2%和51.3%,而30例癌徬組織中均未見α-微管蛋白和MDRI暘性錶達.Western blot檢測結果顯示,α-微管蛋白和MDR1在30例新鮮NSCLC組織中的錶達(0.49±0.06和0.56±0.04)明顯高于相應癌徬肺組織(0.07±0.01,0.65±0.02;t=3.693,t=6.769,P＜0.01).α-微管蛋白在Ⅰ～Ⅱ期與Ⅲ～Ⅳ期NSCLC中的暘性錶達率差異有統計學意義(P＜0.01),在中、高分化NSCLC中的暘性錶達率明顯低于低分化NSCLC(P＜0.01).α-微管蛋白的錶達與患者的年齡、性彆、組織類型、腫瘤大小以及淋巴結轉移無明顯關繫(P＞0.05),MDR1的錶達與患者的年齡、性彆、臨床分期、腫瘤大小、病理分級以及淋巴結轉移無關(P＞0.05).在不同組織類型中,MDR1的錶達水平有較大差異,肺腺癌中的MDR1暘性錶達率明顯高于鱗癌和大細胞癌(P＜0.01).α-微管蛋白和MDR1的錶達與化療療效無關(X2=0.69,X2=1.30,P＞0.05).單因素生存分析顯示,α-微管蛋白和MDR1陰性患者的5年生存率分彆為30.7%和28.5%,明顯高于α-微管蛋白和MDR1暘性錶達患者(13.5%和11.8%),差異有統計學意義(X2=20.69,X2=15.52,P＜0.01).多因素生存分析顯示,α-微管蛋白(RR=3.287,P=0.006)和臨床分期(RR=1.954,P=0.025)可作為獨立的預後指標.α-微管蛋白和MDR1在肺癌組織中的錶達無明顯相關性(r=0.093,P＞0.05).結論 α-微管蛋白和MDR1在肺癌的髮生和噁性進展中有一定作用,聯閤檢測可作為判斷肺癌預後的重要指標.
목적 탐토α-미관단백화다약내약기인1(MDR1)재원발성비소세포폐암(NSCLC)중적표체특정급기림상의의.방법 채용면역조화SP법검측158례NSCLC조직중α-미관단백화MDRI적표체정황,채용Western blot방법검측30례신선NSCLC조직급상응암방정상조직중α-미관단백화MDRI적표체,분석량자표체여폐암생물학특성적관계.결과 α-미관단백화MDRI재NSCLC중적양성표체솔분별위65.2%화51.3%,이30례암방조직중균미견α-미관단백화MDRI양성표체.Western blot검측결과현시,α-미관단백화MDR1재30례신선NSCLC조직중적표체(0.49±0.06화0.56±0.04)명현고우상응암방폐조직(0.07±0.01,0.65±0.02;t=3.693,t=6.769,P＜0.01).α-미관단백재Ⅰ～Ⅱ기여Ⅲ～Ⅳ기NSCLC중적양성표체솔차이유통계학의의(P＜0.01),재중、고분화NSCLC중적양성표체솔명현저우저분화NSCLC(P＜0.01).α-미관단백적표체여환자적년령、성별、조직류형、종류대소이급림파결전이무명현관계(P＞0.05),MDR1적표체여환자적년령、성별、림상분기、종류대소、병리분급이급림파결전이무관(P＞0.05).재불동조직류형중,MDR1적표체수평유교대차이,폐선암중적MDR1양성표체솔명현고우린암화대세포암(P＜0.01).α-미관단백화MDR1적표체여화료료효무관(X2=0.69,X2=1.30,P＞0.05).단인소생존분석현시,α-미관단백화MDR1음성환자적5년생존솔분별위30.7%화28.5%,명현고우α-미관단백화MDR1양성표체환자(13.5%화11.8%),차이유통계학의의(X2=20.69,X2=15.52,P＜0.01).다인소생존분석현시,α-미관단백(RR=3.287,P=0.006)화림상분기(RR=1.954,P=0.025)가작위독립적예후지표.α-미관단백화MDR1재폐암조직중적표체무명현상관성(r=0.093,P＞0.05).결론 α-미관단백화MDR1재폐암적발생화악성진전중유일정작용,연합검측가작위판단폐암예후적중요지표.
Objective To detect the expression of α-tubulin and MDR1 in human non-small cell lung carcinoma(NSCLC),and to clarify their clinical significance.Methods Paraffin embedded tissues from 158 primary non-small lung carcinomas and 30 paracancerous lung tissues were examined for expression of α-tubulin and MDR1 by immunohistochemistry(SP method).30 freshly taken NSCLC tissues were examined by Western blot analysis.The relationship between α-tubulin and MDR1 expression and the biological features of lung carcinoma was analyzed.Results The positive rate of a-tubulin and MDR1 expressions in the lung carcinomas was 65.2% and 51.3%,respectively.There was no expression of either of them in 30 paracancerous lung tissues.Western blot analysis showed that the level of a-tubulin and MDR1 expressions in NSCLC tissues were 0.49 ± 0.06 and 0.56 ± 0.04,respectively,significantly higher than that in paracancerous tissues(0.07 ± 0.01)(t=3.693 and t=6.769,P＜0.01).The positive rate of α-tubulin expression was gradually increased with tumor progression,significantly higher in Ⅲ-Ⅳ stage cancers and in poorly differentiated carcinomas(both P＜0.01).There was a distinct statistically significant difference between stage Ⅰ,stage Ⅱ and Ⅲ,and stage Ⅳ.The positive rate of α-tubulin in wellmoderately differentiated carcinomas was lower than that in poorly differentiated ones.There was no significant correlation with age,sex,tumor size,histological type,clinical TNM system and lymph node metastasis.The positive rate of MDR1 was not correlated with sex,age,tumor size,pathological grading,clinical TNM stages and lymph node metastasis.But the positive rate of MDR1 in adenocarcinotna was significantly higher than that in squamous carcinoma and undifferentiated large cell carcinomas(P＜0.01).α-tubulin and MDR1 expression had no impact on the outcome of chemotherapy(X2=0.69 and 1.30,P＞0.05,respectively).Univariate analysis showed that the 5-year survival rate of patients with negative α-tubulin and MDR1 expression was 30.7% and 28.5%,respectively,significantly higher than that of patients with positive α-tubulin and MDR1 expression(13.5% and 11.8%,respectively)(X2=20.69 and 15.52,P＜0.01,respectively),and multivariate Cox regression analysis showed that α-tubulin(RR=3.287,P=0.006)and clinical TNM stage(RR=1.954,P=0.025)were significantly independent predictive factor for patients with lung cancer,MDR1 and other factors could not be used as an independent predicitive factors.However,there was no significant correlation between the expression of α-tubulin and MDR1 in lung carcinoma(r=0.093,P＞0.05).Conclusion The expression of α-tubulin and MDR1 may play an important role in the development and progression of human non-small cell lung carcinoma.Combined detection could be considered as an important index for predicting prognosis of lung carcinoma.
